Biosimilars

Biosimilar medicines:

We believe that biosimilar medicines represent a significant opportunity for the NHS and patients, and we are working with healthcare professionals and commissioners to help realise their potential and make a positive difference to patients.

Herzuma® (trastuzumab) 150 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

SPC PIL

Remsima® (infliximab) 100 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

SPC PIL

Truxima® (rituximab) 100 mg concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects

SPC PIL

Truxima® (rituximab) 500 mg concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

SPC PIL